Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering

• Financing Event: On May 8, 2026, Restart Life Sciences announced a non-brokered private placement of up to 833,333 units at $0.12 CAD per unit to raise gross proceeds of up to $100,000 CAD.
• Use of Proceeds: Funds are designated for a revolving purchase order (PO) financing arrangement to support manufacturing and fulfillment activities of its subsidiary, Holy Crap Foods Inc., addressing 60-180 day payment cycles in the CPG industry.
• Warrant Terms: Each unit includes one common share and one transferable warrant exercisable at $0.15 CAD for two years.
• Operational Updates: Simultaneous announcement of a Project Manager appointment to oversee scaling of functional food portfolio and issuance of 1,600,000 common shares to officers/directors tied to performance milestones (subject to CSE approval).
• Recent Performance Context: Follows April 2026 revenue report showing $106k total revenue (+46% wholesale YoY) and successful Walmart.ca launch.

• Capital Dilution Risk: The issuance of 833,333 units plus 1,600,000 shares to insiders represents significant dilution relative to the small capital raise ($100k). This is a recurring pattern following the December 2025 financing rounds.
• Cash Flow Dependency: The need for dedicated PO financing confirms that despite revenue growth (April $106k), the company lacks sufficient operating cash flow to fund inventory purchases, highlighting liquidity constraints inherent in CPG models with extended payment terms.
• Related Party Transaction: The 1.6M share issuance to officers/directors is a related party transaction under MI 61-101. While tied to milestones, it signals management prioritizing equity compensation over cash retention during growth phases.
• Valuation Context: At $0.12/unit offering price vs current market price of ~$0.09, the placement trades at a premium but introduces immediate supply pressure and warrant dilution ($0.15 exercise).
• Strategic Alignment: The financing supports the Holy Crap acquisition integration strategy announced in February 2026. It is consistent with previous capital raises (Dec 2025) rather than representing a new strategic pivot.

• Company: Restart Life Sciences Corp. operates as a holding company for health-focused consumer brands.
• Flagship Project: Holy Crap Foods Inc., acquired in February 2026, is the primary revenue driver. It focuses on gut health functional foods (cereals, oatmeal).
• Development Status: Post-acquisition integration phase. Moving from acquisition to scaling distribution (Walmart.ca, Amazon) and product development (new protein SKU with University of Manitoba collaboration).
• Manufacturing: Owns a lease-based manufacturing facility in Gibsons, BC, providing vertical integration but requiring capital for raw materials due to CPG payment cycles.